Clinical Trials
9 trialsNCT05663710 2026-05-05
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06835972 2026-05-04
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05048901 2026-04-09
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan
Phase 1/2 Recruiting
NCT03539822 2026-01-21
CAMILLA
University of Pittsburgh
Phase 1/2 Recruiting
NCT05039281 2025-12-19
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03149822 2025-03-13
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 1/2 Completed
NCT03425201 2024-12-31
NICARAGUA
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 1/2 Completed
NCT03201250 2023-09-08
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
University of Nebraska
Phase 1/2 Terminated
NCT01866293 2017-08-30
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed